论文部分内容阅读
目的观察美施康定对中重度癌痛患者的疗效。方法对86例出现中重度癌痛的晚期肿瘤患者,口服美施康定,从30mg开始12小时口服1次,根据疾病缓解程度,按美施康定疼痛剂量调整计算表递增剂量,直到患者无痛或基本无痛。结果完全缓解:20.93%(18/86),明显缓解:68.60%(59/86),中度缓解:8.14%(7/86),轻度缓解:3.49%(3/86),显效:89.53%(77/86)。不良反应中主要为恶心、呕吐、便秘、头晕、排尿困难等。治疗后生活质量明显改善。结论美施康定治疗中重度癌痛,疗效显著,不良反应轻,能明显改善患者的生活质量。
Objective To observe the curative effect of Mesangkangding on patients with moderate-severe cancer. Methods Eighty-six patients with advanced cancer who had moderate-to-severe cancer pain were treated orally with meclizine orally and once daily for 12 hours from 30 mg. According to the severity of the disease, the dose was adjusted according to the pain dose of mexitumidine until the patient had no pain or Basically painless. The results were completely relieved: 20.93% (18/86), significantly relieved: 68.60% (59/86), moderate relieve: 8.14% (7/86), mild relieve: 3.49% (3/86) % (77/86). Adverse reactions mainly nausea, vomiting, constipation, dizziness, dysuria and so on. After treatment, the quality of life improved significantly. Conclusion Meishi Kangding treatment of moderate and severe cancer pain, significant effect, mild adverse reactions, can significantly improve the quality of life of patients.